Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study

Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study

<b>Background/Objectives:</b> P2X3 receptor antagonists have been suggested as a potential treatment for urogenital, respiratory and pain conditions. This first-in-human (FiH) study evaluated filapixant, a new P2X3 receptor antagonist with high receptor selectivity. It was anticipated th...

Full description

Saved in:
Bibliographic Details
Main Authors: Klaus Francke, Sybille Baumann, Isabella Gashaw, Stefan Klein, Beate Rohde, Oliver Zolk, Oliver M. Fischer, Christian Friedrich
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Pharmaceuticals
Subjects:
dysgeusia
P2X3 receptor antagonists
pharmacokinetics
taste perception
first in human
Online Access:https://www.mdpi.com/1424-8247/18/5/758
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items